Perioperative outcomes and early survival after curative-intent non–small cell lung cancer (NSCLC) resection in a Colombian tertiary center.

e20106 Background: Real-world data on perioperative quality indicators and outcomes after curative-intent NSCLC resection in Latin America remain limited. Regional evidence is needed to assess surgical performance and compare outcomes with international benchmarks. Methods: We conducted a retrospective cohort study of adults undergoing oncologic lung resection with curative intent at Fundación Santa Fe de Bogotá (2018–2025). Kaplan–Meier (KM) estimated 12- and 24-month event rates. OS and DFS were analyzed with log-rank and Cox models (≤2 covariates), and TTR with cumulative incidence functions and Fine– Gray models. Results: A total of 81 patients were included, with 68.8% staged as I–II and 23.8% as stage III. Minimally invasive and open approaches were used in 88.0% and 12.0% of patients, respectively. R0 resection occurred in 71 patients (87.7%). Median length of stay was 5 days (IQR 4–7). At 30 days, conversion occurred in 3.7% of cases, any complication in 7.4%, unplanned readmission in 7.4%, and mortality was 0%. Survival and recurrence outcomes were analyzed in 78 patients. After a median follow-up of 20.7 months (95% CI 15.5–29.9), median survival was not reached. OS, DFS, and TTR event-free were 95.1%/86.2%, 85.7%/75.9%, and 87.4%/79.6% at 12/24 months. Compared with stages I–II, stage III was associated with a nonsignificant reduction in OS (HR 3.69, 95% CI 0.88–15.37) and with significantly worse DFS (HR 11.05, 95% CI 2.94–41.54) and higher TTR (SHR 12.40, 95% CI 3.04–50.56). Surgical margins were not significantly associated with DFS (HR 1.48, 95% CI 0.32–6.85) or TTR (SHR 2.36, 95% CI 0.70–7.96). Conclusions: In this Colombian NSCLC surgical cohort, perioperative outcomes met STS/ESTS benchmarks. Pathologic stage III was the main predictor of DFS and TTR, while margins were not significant. These real-world Latin American data support stage-adapted postoperative surveillance and the feasibility of high-quality curative-intent NSCLC surgery. Quality indicators vs international benchmarks. Indicator Cohort (n=81) International Benchmark (Institution/Source) Intraoperative conversion 3 (3.7%) <10% (STS GTSD/VATS studies) Intraoperative complication 2 (2.5%) <3-5% (STS GTSD) R0 resection 71 (87.7%) >85% minimum target (NCCN/IASLC/CoC; STS 87%) 30-day SSI 4 (4.9%) <5% (STS GTSD) Any 30-day complication 6 (7.4%) <9.1% (STS GTSD) Unplanned 30-day readmission 6 (7.4%) <10% post-pulmonary resection (STS studies) 30-day mortality 0 (0%) <2% (STS GTSD) Hospital length of stay (median [IQR]) 5 [4-7] days (n=72) Median 5-7 days (ESTS/Europe; STS) ESTS: European Society of Thoracic Surgeons; GTSD: General Thoracic Surgery Database; IASLC: International Association for the Study of Lung Cancer; SSI: surgical site infection; NCCN: National Comprehensive Cancer Network; STS: Society of Thoracic Surgeons; VATS: Video-Assisted Thoracoscopic Surgery.